Brief: Ipsen Receives Positive CHMP Opinion For Ojemda
27/02/2026 11:38
Feb 27 (Reuters) - Ipsen SA IPN.PA: IPSEN RECEIVES POSITIVE CHMP OPINION FOR OJEMDA® FOR THE TREATMENT AS MONOTHERAPY OF CHILDREN WITH RELAPSED OR REFRACTORY BRAF-ALTERED PEDIATRIC LOW-GRADE GLIOMA Source text: ID:nGNXcgLHmc Further company coverage: IPN.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients